UCL Cancer Institute


Further publications

  1. Costa JR, Mansour MR: ToTAL1y degraded - rapid dTAG proteolysis of TAL1 in T-cell acute lymphoblastic leukemia. Haematologica 2023.
  2. Nuttall Musson E, Miller RE, Mansour MR, Lockley M, Ledermann JA, Payne EM: Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention. Leukemia 2024, 38:215-8.
  3. Provez L, Putteman T, Landfors M, Roels J, Reunes L, T'Sas S, Van Loocke W, Lintermans B, De Coninck S, Thenoz M, Sleeckx W, Mackowska-Maslak N, Taghon T, Mansour MR, Farah N, Norga K, Vandenberghe P, Kotecha RS, Goossens S, Degerman S, De Smedt R, Van Vlierberghe P: Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma. Cancers (Basel) 2023, 15.
  4. Wilson, A. J., Troy-Barnes, E., Subhan, M., Clark, F., Gupta, R., Fielding, A. K., Kottaridis, P., Mansour, M. R., O'Nions, J., Payne, E., Chavda, N., Baker, R., Thomson, K. & Khwaja, A. Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19. British journal of haematology, doi:10.1111/bjh.16962 (2020).
  5. Hockings, C., Gohil, S., Dowse, R., Hoade, Y., Mansour, M. R., Gale, R. E., Linch, D. C., Rao, A. & Payne, E. M. In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation. British journal of haematology, doi:10.1111/bjh.16322 (2020).
  6. Burt, R., Dey, A., Aref, S., Aguiar, M., Akarca, A., Bailey, K., Day, W., Hooper, S., Kirkwood, A., Kirschner, K., Lee, S. W., Lo Celso, C., Manji, J., Mansour, M. R., Marafioti, T., Mitchell, R. J., Muirhead, R. C., Cheuk Yan Ng, K., Pospori, C., Puccio, I., Zuborne-Alapi, K., Sahai, E. & Fielding, A. K. Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. Blood 134, 1415-1429, doi:10.1182/blood.2019001398 (2019).
  7. Armenteros-Monterroso, E., Zhao, L., Gasparoli, L., Brooks, T., Pearce, K., Mansour, M. R., Martens, J. H. A., de Boer, J. & Williams, O. The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia. Leukemia, doi:10.1038/s41375-019-0495-8 (2019).
  8. Gjini, E., Jing, C. B., Nguyen, A. T., Reyon, D., Gans, E., Kesarsing, M., Peterson, J., Pozdnyakova, O., Rodig, S. J., Mansour, M. R., Joung, K. & Look, A. T. Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish. Dis Model Mech 12, doi:10.1242/dmm.035790 (2019).
  9. He S, Mansour MR, Zimmerman MW, Ki DH, Layden HM, Akahane K, Gjini E, de Groh ED, Perez-Atayde AR, Zhu S, Epstein JA, Look AT. Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. eLife. 2016;5. PubMed PMID: 27130733. 
  10. Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia. 2015 Jul 23. PubMed PMID: 26202935.
  11. Akahane K, Sanda T, Mansour MR, Radimerski T, DeAngelo DJ, Weinstock DM, Look AT. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia. 2015 Aug 12. PubMed PMID: 26265185.
  12. Barcelo C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arevalo Lobo VJ, Real FX, Capella G, Estanyol JM, Jaumot M, Look AT, Agell N. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Gastroenterology. 2014 Oct;147(4):882-92 e8. PubMed PMID: 24998203.
  13. Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT, Feng H. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia. 2014 May;28(5):1145-8. PubMed PMID: 24342948.
  14. Shochat C, Tal N, Gryshkova V, Birger Y, Bandapalli OR, Cazzaniga G, Gershman N, Kulozik AE, Biondi A, Mansour MR, Twizere JC, Muckenthaler MU, Ben-Tal N, Constantinescu SN, Bercovich D, Izraeli S. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood. 2014 Jul 3;124(1):106-10. PubMed PMID: 24787007.
  15. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British journal of haematology. 2013 Apr;161(1):117-27. PubMed PMID: 23373539.
  16. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, Look AT. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2012 Jul 31. PubMed PMID: 22847027.
  17. Jenkinson S, Koo K, Mansour MR, Goulden N, Vora A, Mitchell C, Wade R, Richards S, Hancock J, Moorman AV, Linch DC, Gale RE. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2012 Jul 3. PubMed PMID: 22814294.
  18. Mansour MR, Look AT. Discovery of a secreted tumor suppressor provides a promising therapeutic strategy for follicular lymphoma. Cancer Cell. 2011 Nov 15;20(5):559-61. PubMed PMID: 22094251.
  19. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA. WT1 mutations in T-ALL. Blood. 2009;114(5):1038-45.
  20. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009 Dec 10;114(25):5136-45. PubMed PMID: 19828704.
  21. Gordon WR, Roy M, Vardar-Ulu D, Garfinkel M, Mansour MR, Aster JC, Blacklow SC. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood. 2009;113(18):4381-90.
  22. Mansour MR. Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma. Expert Rev Hematol. 2009 Apr;2(2):133-6. PubMed PMID: 21083447.
  23. Mansour MR, Duke V, Foroni L, Patel B, Allen CG, Ancliff PJ, Gale RE, Linch DC. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2007;13(23):6964-9.
  24. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 2007 Jun 21;447(7147):966-71. PubMed PMID: 17515920.
  25. Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia. 2006;20(3):537-9.